HER2 overexpression in urothelial carcinoma with <i>GATA3</i> and <i>PPARG</i> copy number gains
2024 · The Oncologist · 9 citations
https://doi.org/10.1093/oncolo/oyae127
T
Tanya Jindal
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
64
Papers
346
Citations
9
h-index
9
i10-index
Tanya Jindal is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers & Urinary and Genital Oncology Studies. The author has an h-index of 9, co-authored 55 publications.
ORCID: 0000-0001-5954-3278Papers by this author
worksGenomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data
2024 · European Urology Oncology · 6 citations
https://doi.org/10.1016/j.euo.2024.12.006
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
2024 · Clinical Genitourinary Cancer · 1 citations
https://doi.org/10.1016/j.clgc.2024.102284
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database
2026 · Clinical Genitourinary Cancer · 0 citations
https://doi.org/10.1016/j.clgc.2026.102501
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat